BIOLASE Expects Revenue to Approximate $15.25 Million for 2013 Fourth Quarter

BIOLASE Expects Revenue to Approximate $15.25 Million for 2013 Fourth Quarter 
Represents Second Strongest Quarter of Revenue Since Termination of
Exclusive Distribution Agreement With Henry Schein in August 2010 
Q4 2013 Reorganization and Expansion of Sales Force and Marketing
Department Expected to Be Completed in Q1 2014 
IRVINE, CA -- (Marketwired) -- 02/06/14 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, including the Company's proprietary WaterLase(R), and a
pioneer in laser surgery in other medical specialties, as well as a
distributor of digital radiography and GALAXY BioMill(TM) CAD/CAM
systems for dentistry, today announced that, based on a preliminary
review of its financial performance for the fourth quarter ended
December 31, 2013, the Company expects to report net revenue of
approximately $15.25 million. 
"Based on our preliminary unaudited results, the fourth quarter ended
December 31, 2013 is shaping up to be BIOLASE's(R) second strongest
revenue quarter since the termination of our global distribution
arrangement with Henry Schein in August 2010," said Federico
Pignatelli, Chairman and CEO. "Fiscal 2013 has been a year of
transition and consolidation for BIOLASE after two years of rapid
growth. We have broadened our dental product line with a new diode
laser line, the EPIC(TM), and grown our BIOLASE DaVinci Imaging(TM)
business, which included the introduction of the GALAXY BioMill
chair-side milling machine. Together with our NewTom(TM) cone beam
and digital radiography products and 3Shape Trios(R) intraoral
scanners, BIOLASE now offers the most diverse and complete line of
high-tech dental product offerings in North America, as well as
several international markets. 
"We invested heavily in fiscal 2013 in order to increase our dental
product offerings and build the infrastructure necessary to support
this expansion. This was achieved while we continued the expansion of
our technology into other medical markets, as well. We believe that
our breakthrough WaterLase and diode technologies, coupled with our
other high tech products, have the potential to greatly improve the
clinical outcomes of a variety of surgical procedures in multiple
medical fields. 
"While 2013 has seen higher expenses and lower gross margins for
BIOLASE, the result is a stronger foundation for our core dental
business as we enter 2014. We do not expect these higher
expansion-related expenses to continue in 2014. Further, we are also
extremely enthusiastic about the potential that our highly promising
new preclinical laser, code named DRAGON, gives us to enter several
new medical markets, and the revenue opportunities that go along with
them," concluded Pignatelli. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners and
in-office milling machines; products that are focused on technologies
that advance the practice of dentistry and medicine. The Company's
proprietary laser products incorporate approximately 300 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its innovative products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are revolutionary dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental
imaging equipment. BIOLASE has sold more than 24,800 lasers. Other
laser products under development address ophthalmology and other
medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Google+ at
www.google.com/+BIOLASEIrvine, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos.  
BIOLASE(R), WaterLase(R), EPIC(TM), GALAXY BioMill(TM), and BIOLASE
DaVinci Imaging(TM) are registered trademarks or trademarks of
BIOLASE, Inc. 
Trios(R) is a registered trademark of 3Shape A/S LLC and NewTom(TM)
is a trademark of QR S.r.l. Corporation, a wholly-owned subsidiary of
Cefla Capital Services, S.p.A. 
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
 Statements contained in this press release that refer to
BIOLASE's estimated or anticipated future results or other
non-historical facts are forward-looking statements, as are any
statements in this press release concerning prospects related to
BIOLASE's strategic initiatives, product introductions and
anticipated financial performance. Forward-looking statements can
also be identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
"may," "will," and variations of these words or similar expressions.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect BIOLASE's current
perspective of existing trends and information and speak only as of
the date of this release. Actual results may differ materially from
BIOLASE's current expectations depending upon a number of factors
affecting BIOLASE's business. These factors include, among others,
adverse changes in general economic and market conditions,
competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of
new product offerings and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein.  
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
212-564-4700 
 
 
Press spacebar to pause and continue. Press esc to stop.